Covariates predictive of shorter survival among patients given gemtuzumab ozogamicin (GO) with or without interleukin 11 (IL-11; n = 51) or idarubicin plus cytosine arabinoside (n = 31)
Covariate . | Posterior mean (SD) . | Posterior probability of harmful effect . |
---|---|---|
Performance status 3 or 4 | 0.672 (0.241) | 0.996 |
Treatment in laminar-airflow room | −0.969 (0.206) | 0.000 |
Cytogenetic finding of −5/−7 | 1.230 (0.239) | 1.000 |
Other cytogenetic abnormalities | 0.679 (0.234) | 0.998 |
Treatment with GO with or without IL-11 | 0.823 (0.323) | 0.995 |
Covariate . | Posterior mean (SD) . | Posterior probability of harmful effect . |
---|---|---|
Performance status 3 or 4 | 0.672 (0.241) | 0.996 |
Treatment in laminar-airflow room | −0.969 (0.206) | 0.000 |
Cytogenetic finding of −5/−7 | 1.230 (0.239) | 1.000 |
Other cytogenetic abnormalities | 0.679 (0.234) | 0.998 |
Treatment with GO with or without IL-11 | 0.823 (0.323) | 0.995 |